Lowinson and Ruiz's Substance Abuse

• Pedro Ruiz MD
• Professor and Executive Vice Chair, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami FL

• Eric Strain MD
• Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

• Edition: Fifth
• Product Format: Hardbound
• ISBN: 9781605472775
• Trim Size: 8.375 x 10.875
• Pages: 1074
• Pub Date: Apr 15, 2011
• Weight: 5.0

Preface vii Foreword ix S E C T I O N 1 : Foundations 1 Historical Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . 1 David F. Musto and Eric D. Wish 2 Epidemiology—The United States . . . . . . . . . . . . . . . 17 Charles Winick and Jack Levinson 3 Epidemiology—A European Perspective . . . . . . . . . . 26 Icro Maremmani, Matteo Pacini, Mercedes Lovrecic, and Pier Paolo Pani S E C T I O N 2 : Determinants of Abuse and Dependence 4 Genetic Factors in the Risk for Substance Use Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Thomas A. Nguyen, Jaimee L. Heffner, Show W. Lin, and Robert M. Anthenelli 5 Neurobiological Factors of Drug Dependence and Addiction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 Heath D. Schmidt, Fair M. Vassoler, and R. Christopher Pierce 6 Psychological Factors (In Determinants of Abuse and Dependence) . . . . . . . . . . . . . . . . . . . . . . . 79 Steven Shoptaw 7 Behavioral Aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 Kenneth Silverman, Anthony DeFulio, and Jeffery J. Everly 8 Sociocultural Factors and Their Implications . . . . . . 99 Nady el-Guebaly and Pedro Ruiz S E C T I O N 3 : Evaluation 9 Clinical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107 LaVerne Hanes Stevens and Michael L. Dennis 10 Diagnosis and Classification: DSM-IV-TR and ICD-10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117 George E. Woody and John Cacciola 11 Diagnostic Laboratory: Screening for Drug Abuse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123 Karl G. Verebey and Gerard Meenan S E C T I O N 4 : Substances of Abuse 12 Alcohol Use Disorders . . . . . . . . . . . . . . . . . . . . . . . . 138 Carlos A. Hernandez-Avila and Henry R. Kranzler 13 Opioids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 David H. Epstein, Karran A. Phillips, and Kenzie L. Preston 14 Cocaine and Crack . . . . . . . . . . . . . . . . . . . . . . . . . . . 191 Richard P. Paczynski and Mark S. Gold 15 Cannabis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214 Alan J. Budney, Ryan L. Vandrey, and Stephanie Fearer 16 Amphetamines and Other Stimulants . . . . . . . . . . . 238 Kevin P. Hill and Roger D. Weiss 17 Sedative–Hypnotics . . . . . . . . . . . . . . . . . . . . . . . . . . 255 Domenic A. Ciraulo and Clifford Knapp 18 Hallucinogens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267 Robert N. Pechnick and Kathryn A. Cunningham 19 PCP/Designer Drugs/MDMA . . . . . . . . . . . . . . . . . . 277 Una D. McCann 20 Inhalants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284 Charles W. Sharp, Matthew O. Howard, and Wynne K. Schiffer 21 Nicotine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 319 Joy M. Schmitz and Angela L. Stotts 22 Caffeine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335 Laura M. Juliano, Britta L. Anderson, and Roland R. Griffiths 23 Anabolic–Androgenic Steroids . . . . . . . . . . . . . . . . . 354 Laurence M. Westreich S E C T I O N 5 : Compulsive and Addictive Behaviors 24 Eating Disorders and Substance Use Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 373 Harry A. Brandt, Steven F. Crawford, and Katherine A. Halmi 25 Pathologic Gambling . . . . . . . . . . . . . . . . . . . . . . . . . 384 Elise E. DeVito and Marc Potenza 26 Sexual Addiction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 393 Virginia A. Sadock 27 Internet Addiction . . . . . . . . . . . . . . . . . . . . . . . . . . . 284 Philippe Weintraub, Thomas M. Dunn, Joel Yager, and Zebulon Taintor S E C T I O N 6 : Treatment Approaches Part 1: Neurobiologic Treatments 28 Methadone Maintenance . . . . . . . . . . . . . . . . . . . . . . 419 Andrew J. Saxon and Karen Miotto 29 Buprenorphine in the Treatment of Opioid Dependence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437 D. Andrew Tompkins and Eric C. Strain 30 Naltrexone Pharmacotherapy . . . . . . . . . . . . . . . . . . 447 Emily Harrison and Ismene Petrakis 31 Vaccines for Substance Abuse . . . . . . . . . . . . . . . . . . 457 Frank M. Orson, Mark J. Biscone, Berma M. Kinsey, and Thomas R. Kosten 32 Acupuncture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 466 Ji-Sheng Han and Cai-Lian Cui 33 Alcohol Abstinence Management . . . . . . . . . . . . . . . 477 Richard N. Rosenthal 34 Alternative Pharmacotherapies for Opioid Addiction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 494 Paul J. Fudala and Rolley E. Johnson 35 Sedative-Hypnotics Abstinence . . . . . . . . . . . . . . . . . 501 R.C. Oude Voshaar 36 Nicotine Dependence Management . . . . . . . . . . . . . 510 Douglas Ziedonis, David Kalman, Chris W. Johnson, and Lisa A. Mistler Part 2: Psychosocial and Other Treatments 37 Self-Help Programs Focused on Substance Use: Active Ingredients and Outcomes . . . . . . . . . . . . . . . 523 Rudolf H. Moos and Christine Timko 38 Alternative Support Groups . . . . . . . . . . . . . . . . . . . . 533 Arthur T. Horvath 39 The Therapeutic Community . . . . . . . . . . . . . . . . . . 543 William B. OÆBrien, J. Gabriel Piedrahita, and Francisco (Sebastian) P. Bacatan, Jr. 40 Network Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 551 Marc Galanter and Helen Dermatis 41 Individual Psychotherapy . . . . . . . . . . . . . . . . . . . . . 562 Joan E. Zweben 42 Group Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 575 Arnold M. Washton 43 Family/Couples Approaches to Treatment Engagement and Therapy . . . . . . . . . . . . . . . . . . . . . 584 William Fals-Stewart and Wendy K. K. Lam 44 Cognitive Behavioral Therapy . . . . . . . . . . . . . . . . . . 593 Kathleen M. Carroll 45 Contingency Management in the Treatment of Substance Use Disorders: Trends in the Literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603 Stephen T. Higgins, Stacey C. Sigmon, and Sarah H. Heil 46 Motivational Interviewing and Enhancement . . . . . 622 Carlo C. DiClemente, Onna R. Van Orden, and Katherine S. Wright 47 Relapse Prevention . . . . . . . . . . . . . . . . . . . . . . . . . . . 633 Dennis C. Daley, G. Alan Marlatt, and Antoine Douaihy S E C T I O N 7 : Management of Associated Medical Conditions 48 Maternal and Neonatal Complications of Alcohol and Other Drugs . . . . . . . . . . . . . . . . . . . . . . 648 Karol Kaltenbach and Hendr\u00e9e Jones 49 Medical Complications of Drug Use/Dependence . . 663 Joshua D. Lee, Jennifer McNeely, and Marc N. Gourevitch 50 Psychiatric Complications of HIV-1 Infection and Drug Abuse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 682 Harold W. Goforth, L. Brett Caram, Jorge Maldonado, Pedro Ruiz, and Francisco Fernandez 51 Acute and Chronic Pain . . . . . . . . . . . . . . . . . . . . . . . 695 Russell K. Portenoy 52 Substance Use Disorders in Individuals with Co-occurring Psychiatric Disorders . . . . . . . . . . . . . 721 Sylvia J. Dennison 53 Medication Interactions . . . . . . . . . . . . . . . . . . . . . . . 730 Carolina L. Haass-Koffler and Elinore F. McCance-Katz S E C T I O N 8 : Models of Prevention 54 School-Based Programs . . . . . . . . . . . . . . . . . . . . . . . 742 Gilbert J. Botvin and Kenneth W. Griffin 55 Harm Reduction: New Drug Policies and Practices . . 754 Ernest Drucker, Robert G. Newman, Ethan Nadelmann, Alex Wodak, Daniel Wolfe, David